Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


19.02.2024

1 Am J Ind Med
2 Am J Respir Crit Care Med
5 BMC Cancer
1 Br J Cancer
5 Cancer
3 Cancer Cell
2 Cancer Res
2 Cancer Sci
3 Chest
1 Clin Cancer Res
2 Clin Lung Cancer
3 Eur J Cancer
2 Int J Cancer
3 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
9 J Thorac Cardiovasc Surg
4 J Thorac Oncol
1 JAMA Oncol
5 Lung Cancer
1 Nat Med
2 PLoS One
1 Science
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Ind Med

  1. RINGEN K, Dement J, Cloeren M, Almashat S, et al
    Mortality of older construction and craft workers employed at Department of Energy (DOE) nuclear sites: Follow-up through 2021.
    Am J Ind Med. 2024;67:261-273.
    PubMed         Abstract available


    Am J Respir Crit Care Med

  2. GUPTA N, Johnson SR
    Lymphangioleiomyomatosis: No Longer Ultra-rare.
    Am J Respir Crit Care Med. 2024;209:358-359.
    PubMed        

  3. LYNN E, Forde SH, Franciosi AN, Bendstrup E, et al
    Updated Prevalence of Lymphangioleiomyomatosis in Europe.
    Am J Respir Crit Care Med. 2024;209:456-459.
    PubMed        


    BMC Cancer

  4. HUANG CY, Hsieh MS, Hsieh PC, Wu YK, et al
    Pulmonary rehabilitation improves exercise capacity, health-related quality of life, and cardiopulmonary function in patients with non-small cell lung cancer.
    BMC Cancer. 2024;24:211.
    PubMed         Abstract available

  5. THAMRONGJIRAPAT T, Muntham D, Incharoen P, Trachu N, et al
    Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer.
    BMC Cancer. 2024;24:200.
    PubMed         Abstract available

  6. YIN H, Jia W, Yu J, Zhu H, et al
    Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
    BMC Cancer. 2024;24:197.
    PubMed         Abstract available

  7. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
    Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
    BMC Cancer. 2024;24:191.
    PubMed         Abstract available

  8. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    PubMed         Abstract available


    Br J Cancer

  9. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Correction: Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02603.
    PubMed        


    Cancer

  10. NIERENGARTEN MB
    Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC.
    Cancer. 2024;130:495-496.
    PubMed        

  11. RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al
    A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240.
    PubMed        

  12. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    PubMed         Abstract available

  13. DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al
    Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250.
    PubMed         Abstract available

  14. NIERENGARTEN MB
    Updated American Cancer Society lung cancer screening guidelines: The new guidelines offer expanded criteria recommended for lung cancer screening based on age, smoking status, and smoking history.
    Cancer. 2024;130:656-657.
    PubMed        


    Cancer Cell

  15. HUANG DD, Yang JC
    Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
    Cancer Cell. 2024;42:172-174.
    PubMed         Abstract available

  16. BENGUIGUI M, Cooper TJ, Kalkar P, Schif-Zuck S, et al
    Interferon-stimulated neutrophils as a predictor of immunotherapy response.
    Cancer Cell. 2024;42:253-265.
    PubMed         Abstract available

  17. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2024;42:318-322.
    PubMed        


    Cancer Res

  18. ALEWINE C
    Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis.
    Cancer Res. 2024;84:513-514.
    PubMed         Abstract available

  19. HU B, Wiesehofer M, de Miguel FJ, Liu Z, et al
    ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
    Cancer Res. 2024 Feb 15. doi: 10.1158/0008-5472.CAN-23-0438.
    PubMed         Abstract available


    Cancer Sci

  20. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
    Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
    Cancer Sci. 2024;115:507-528.
    PubMed         Abstract available

  21. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
    Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
    Cancer Sci. 2024;115:357-368.
    PubMed         Abstract available


    Chest

  22. WORTHY T, Jones A, Yang BE, Ishiwata-Endo H, et al
    Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis.
    Chest. 2024;165:303-306.
    PubMed        

  23. OST DE
    A PLUS Prediction Model Provides Insights Into the Probability of Mediastinal Metastasis.
    Chest. 2024;165:248-249.
    PubMed        

  24. KUNITOMO Y, Sather P, Killam J, Pisani M, et al
    Impact of structured reporting for lung cancer screening low-dose CT scan incidental findings on physician management.
    Chest. 2024 Feb 10:S0012-3692(24)00147-8. doi: 10.1016/j.chest.2024.
    PubMed        


    Clin Cancer Res

  25. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    PubMed         Abstract available


    Clin Lung Cancer

  26. KAMIGAICHI A, Hamada A, Tsuboi M, Yoshimura K, et al
    A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial).
    Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00006.
    PubMed         Abstract available

  27. OKUMA Y, Shintani Y, Sekine I, Shukuya T, et al
    Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Data
    Clin Lung Cancer. 2024 Feb 2:S1525-7304(24)00007.
    PubMed         Abstract available


    Eur J Cancer

  28. BRAHMER JR, Long GV, Hamid O, Garon EB, et al
    Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
    Eur J Cancer. 2024;199:113530.
    PubMed         Abstract available

  29. EBSTEIN E, Brocard P, Soussi G, Khoury R, et al
    Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.
    Eur J Cancer. 2024;200:113604.
    PubMed         Abstract available

  30. CATOZZI S, Assaad S, Delrieu L, Favier B, et al
    Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.
    Eur J Cancer. 2024;199:113571.
    PubMed         Abstract available


    Int J Cancer

  31. MULSHINE JL, Avila RS, Rizzo AA, Estepar RSJ, et al
    Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to optimize population health final summary.
    Int J Cancer. 2024;154:1365-1370.
    PubMed         Abstract available

  32. WELSCH E, Holzer B, Schuster E, Fabikan H, et al
    Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation.
    Int J Cancer. 2024 Feb 14. doi: 10.1002/ijc.34886.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  33. FARLEY A, Nelson B
    Neoadjuvant Chemoimmunotherapy for Initially Resectable Non-Small Cell Lung Cancer: Queen's Gambit or CheckMate?
    Int J Radiat Oncol Biol Phys. 2024;118:585-586.
    PubMed        

  34. SHUJA M, Owen D
    What if Perioperative Therapy for Non-Small Cell Lung Cancer Renders Someone Inoperable?
    Int J Radiat Oncol Biol Phys. 2024;118:587.
    PubMed        

  35. HAN C, Qiu J, Bai L, Liu T, et al
    Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024 Feb 13:S0360-3016(24)00298.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  36. XIA X, Ge Y, Ge F, Gu P, et al
    MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:88.
    PubMed         Abstract available

  37. ZHOU W, Yeerkenbieke G, Zhang Y, Zhou M, et al
    Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
    J Cancer Res Clin Oncol. 2024;150:90.
    PubMed         Abstract available

  38. KURIBAYASHI T, Ohashi K, Nishii K, Ninomiya K, et al
    Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2024;150:89.
    PubMed         Abstract available


    J Natl Cancer Inst

  39. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    PubMed         Abstract available


    J Nucl Med

  40. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
    PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
    J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
    PubMed         Abstract available


    J Thorac Cardiovasc Surg

  41. COOPER A, Chaft JE, Bott MJ
    Induction Therapy for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 12:S0022-5223(24)00160.
    PubMed        


  42. Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 10:S0022-5223(24)00022.
    PubMed        

  43. KOREVAAR DA, Annema JT
    Targeted versus systematic nodal staging in early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 8:S0022-5223(24)00004.
    PubMed        


  44. Discussion to: AATS 2023: Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
    J Thorac Cardiovasc Surg. 2024;167:859-860.
    PubMed        

  45. ZHANG C, Pan Y, Li H, Zhang Y, et al
    Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
    J Thorac Cardiovasc Surg. 2024;167:797-809.
    PubMed         Abstract available

  46. DEBOEVER N, Bayley EM, Eisenberg MA, Hofstetter WL, et al
    Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
    J Thorac Cardiovasc Surg. 2024;167:814-819.
    PubMed         Abstract available

  47. SACHDEVA UM
    Commentary: The genes stand alone: Genetic risk factors predict early pulmonary recurrence of colorectal carcinoma metastases.
    J Thorac Cardiovasc Surg. 2024;167:820-821.
    PubMed        

  48. STEIMER D, Coughlin JM, Yates E, Xie Y, et al
    Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
    J Thorac Cardiovasc Surg. 2024;167:849-858.
    PubMed         Abstract available


  49. Discussion to: Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
    J Thorac Cardiovasc Surg. 2024;167:810-811.
    PubMed        


    J Thorac Oncol

  50. OWONIKOKO TK
    SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
    J Thorac Oncol. 2024;19:193-195.
    PubMed        

  51. LE X
    Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:190-192.
    PubMed        

  52. LEE JH
    Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
    J Thorac Oncol. 2024;19:187-189.
    PubMed        

  53. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
    Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
    J Thorac Oncol. 2024;19:337-343.
    PubMed         Abstract available


    JAMA Oncol

  54. TEWARI KS, Colombo N, Monk BJ, Dubot C, et al
    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410.
    PubMed         Abstract available


    Lung Cancer

  55. SAIGI M, Mate JL, Carcereny E, Martinez-Cardus A, et al
    HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
    Lung Cancer. 2024;189:107502.
    PubMed         Abstract available

  56. WANG S, Hao X, Dai L, Lou N, et al
    Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
    Lung Cancer. 2024;189:107503.
    PubMed         Abstract available

  57. PAZ-ARES L, Goto Y, Wan-Teck Lim D, Halmos B, et al
    Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase
    Lung Cancer. 2024;189:107451.
    PubMed         Abstract available

  58. VAN ZANDWIJK N, Frank AL
    A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC).
    Lung Cancer. 2024 Jan 17:107474. doi: 10.1016/j.lungcan.2024.107474.
    PubMed        

  59. WANG Y, Hu C, Yu H, Hu J, et al
    Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
    Lung Cancer. 2024;189:107495.
    PubMed         Abstract available


    Nat Med

  60. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    PubMed         Abstract available


    PLoS One


  61. Expression of Concern: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2024;19:e0299045.
    PubMed        

  62. TIAN P, Du D, Yang L, Zhou N, et al
    SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.
    PLoS One. 2024;19:e0298295.
    PubMed         Abstract available


    Science

  63. GARDNER EE, Earlie EM, Li K, Thomas J, et al
    Lineage-specific intolerance to oncogenic drivers restricts histological transformation.
    Science. 2024;383:eadj1415.
    PubMed         Abstract available


    Thorax

  64. DAFFRE E, Porcher R, Iannelli A, Prieto M, et al
    Protective effect of height on long-term survival of resectable lung cancer: a new feature of the lung cancer paradox.
    Thorax. 2024 Feb 15:thorax-2023-220443. doi: 10.1136/thorax-2023-220443.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.